CHRISTOPHER SCRUGGS: Open Payments
NPI 1659994044 · OXFORD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$790 in 36 payments from 17 companies in 2025. Trend: 2023 $1,760 · 2024 $903 · 2025 $790
Food & beverage: $790
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 8 | $216 |
| Sumitomo Pharma America, Inc. | 7 | $147 |
| Dendreon Pharmaceuticals LLC | 4 | $102 |
| PFIZER INC. | 3 | $48 |
| Novartis Pharmaceuticals Corporation | 2 | $41 |
| UROGEN PHARMA, INC. | 1 | $31 |
| Antares Pharma, Inc. | 1 | $26 |
| Olympus America Inc. | 1 | $25 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $20 |
| IMMUNITYBIO, INC. | 1 | $20 |
Products named: ERLEADA, PROVENGE, GEMTESA, XTANDI, ORGOVYX, PLUVICTO, XYOSTED, iTIND System.
Industry payments across MS — which companies pay providers there.
